Isolated pulmonary vasculitis associated with nilotinib use: A case report

An association between tyrosine-kinase inhibitor therapy for chronic myeloid leukemia and vascular adverse events including peripheral arterial disease, coronary artery disease, and pulmonary hypertension has been described. We present a patient who developed isolated pulmonary artery vasculitis res...

Full description

Bibliographic Details
Main Authors:	Nicolette T. Morris, Mihaela B. Taylor, Melkon Hacobian, Olga M. Olevsky, Tanaz A. Kermani
Format:	Article
Language:	English
Published:	Elsevier 2020-01-01
Series:	Leukemia Research Reports
Subjects:	Chronic myeloid leukemia Large vessel vasculitis Pulmonary vasculitis Pulmonary arteritis Arteritis Vasculitis
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213048920300200

id	doaj-e0f9adfc9f074798b80565d7a3e6c325
record_format	Article
spelling	doaj-e0f9adfc9f074798b80565d7a3e6c3252020-12-19T05:05:48ZengElsevierLeukemia Research Reports2213-04892020-01-0114100214Isolated pulmonary vasculitis associated with nilotinib use: A case reportNicolette T. Morris0Mihaela B. Taylor1Melkon Hacobian2Olga M. Olevsky3Tanaz A. Kermani4Division of Rheumatology, University of California, Los Angeles, David Geffen School of Medicine, California, USADivision of Rheumatology, University of California, Los Angeles, David Geffen School of Medicine, California, USAUniversity of California, Los Angeles, David Geffen School of Medicine, California, USADivision of Hematology, University of California, Los Angeles, David Geffen School of Medicine, California, USADivision of Rheumatology, University of California, Los Angeles, David Geffen School of Medicine, California, USA; Corresponding author.An association between tyrosine-kinase inhibitor therapy for chronic myeloid leukemia and vascular adverse events including peripheral arterial disease, coronary artery disease, and pulmonary hypertension has been described. We present a patient who developed isolated pulmonary artery vasculitis resulting in left pulmonary artery stenosis, in addition to left coronary artery stenosis while on nilotinib. While monitoring for cardiovascular events is important, clinicians should also recognize possible drug-induced vasculitis during chronic nilotinib therapy.http://www.sciencedirect.com/science/article/pii/S2213048920300200Chronic myeloid leukemiaLarge vessel vasculitisPulmonary vasculitisPulmonary arteritisArteritisVasculitis
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Nicolette T. Morris Mihaela B. Taylor Melkon Hacobian Olga M. Olevsky Tanaz A. Kermani
spellingShingle	Nicolette T. Morris Mihaela B. Taylor Melkon Hacobian Olga M. Olevsky Tanaz A. Kermani Isolated pulmonary vasculitis associated with nilotinib use: A case report Leukemia Research Reports Chronic myeloid leukemia Large vessel vasculitis Pulmonary vasculitis Pulmonary arteritis Arteritis Vasculitis
author_facet	Nicolette T. Morris Mihaela B. Taylor Melkon Hacobian Olga M. Olevsky Tanaz A. Kermani
author_sort	Nicolette T. Morris
title	Isolated pulmonary vasculitis associated with nilotinib use: A case report
title_short	Isolated pulmonary vasculitis associated with nilotinib use: A case report
title_full	Isolated pulmonary vasculitis associated with nilotinib use: A case report
title_fullStr	Isolated pulmonary vasculitis associated with nilotinib use: A case report
title_full_unstemmed	Isolated pulmonary vasculitis associated with nilotinib use: A case report
title_sort	isolated pulmonary vasculitis associated with nilotinib use: a case report
publisher	Elsevier
series	Leukemia Research Reports
issn	2213-0489
publishDate	2020-01-01
description	An association between tyrosine-kinase inhibitor therapy for chronic myeloid leukemia and vascular adverse events including peripheral arterial disease, coronary artery disease, and pulmonary hypertension has been described. We present a patient who developed isolated pulmonary artery vasculitis resulting in left pulmonary artery stenosis, in addition to left coronary artery stenosis while on nilotinib. While monitoring for cardiovascular events is important, clinicians should also recognize possible drug-induced vasculitis during chronic nilotinib therapy.
topic	Chronic myeloid leukemia Large vessel vasculitis Pulmonary vasculitis Pulmonary arteritis Arteritis Vasculitis
url	http://www.sciencedirect.com/science/article/pii/S2213048920300200
work_keys_str_mv	AT nicolettetmorris isolatedpulmonaryvasculitisassociatedwithnilotinibuseacasereport AT mihaelabtaylor isolatedpulmonaryvasculitisassociatedwithnilotinibuseacasereport AT melkonhacobian isolatedpulmonaryvasculitisassociatedwithnilotinibuseacasereport AT olgamolevsky isolatedpulmonaryvasculitisassociatedwithnilotinibuseacasereport AT tanazakermani isolatedpulmonaryvasculitisassociatedwithnilotinibuseacasereport
_version_	1724377928105459712

Isolated pulmonary vasculitis associated with nilotinib use: A case report

Similar Items